139.98
price down icon0.15%   -0.21
pre-market  Pre-market:  140.30   0.32   +0.23%
loading
Biogen Inc stock is traded at $139.98, with a volume of 1.25M. It is down -0.15% in the last 24 hours and up +1.11% over the past month. Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$140.19
Open:
$140.36
24h Volume:
1.25M
Relative Volume:
0.86
Market Cap:
$20.49B
Revenue:
$9.61B
Net Income/Loss:
$1.62B
P/E Ratio:
12.64
EPS:
11.07
Net Cash Flow:
$1.77B
1W Performance:
-5.01%
1M Performance:
+1.11%
6M Performance:
-28.45%
1Y Performance:
-38.22%
1-Day Range:
Value
$139.05
$143.50
1-Week Range:
Value
$139.05
$157.09
52-Week Range:
Value
$128.51
$238.00

Biogen Inc Stock (BIIB) Company Profile

Name
Name
Biogen Inc
Name
Phone
(781) 464-2000
Name
Address
225 BINNEY STREET, CAMBRIDGE, MA
Name
Employee
7,605
Name
Twitter
@biogen
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
BIIB's Discussions on Twitter

Compare BIIB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
BIIB
Biogen Inc
139.98 20.49B 9.61B 1.62B 1.77B 11.07
Drug Manufacturers - General icon
LLY
Lilly Eli Co
801.65 720.02B 45.04B 10.59B 414.30M 11.71
Drug Manufacturers - General icon
ABBV
Abbvie Inc
211.55 373.46B 56.33B 4.28B 17.83B 2.40
Drug Manufacturers - General icon
JNJ
Johnson Johnson
162.99 344.63B 88.82B 14.07B 18.06B 5.79
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
75.89 336.88B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
MRK
Merck Co Inc
94.71 251.88B 64.17B 17.12B 18.10B 6.73

Biogen Inc Stock (BIIB) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-11-25 Initiated Bernstein Mkt Perform
Jan-02-25 Downgrade Piper Sandler Overweight → Neutral
Dec-20-24 Downgrade BMO Capital Markets Outperform → Market Perform
Dec-16-24 Downgrade Stifel Buy → Hold
Dec-10-24 Resumed BofA Securities Neutral
Dec-09-24 Downgrade Jefferies Buy → Hold
Nov-18-24 Downgrade Needham Buy → Hold
Nov-15-24 Initiated Wolfe Research Peer Perform
Nov-14-24 Initiated Citigroup Neutral
Oct-31-24 Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-10-24 Resumed Raymond James Mkt Perform
Feb-14-24 Reiterated Needham Buy
Feb-14-24 Downgrade Wells Fargo Overweight → Equal Weight
Jan-24-24 Downgrade UBS Buy → Neutral
Dec-20-23 Resumed Cantor Fitzgerald Overweight
Dec-07-23 Upgrade Raymond James Mkt Perform → Outperform
Sep-06-23 Initiated HSBC Securities Buy
Jul-27-23 Initiated Scotiabank Sector Outperform
Jul-24-23 Reiterated UBS Buy
May-01-23 Upgrade Guggenheim Neutral → Buy
Apr-17-23 Upgrade Piper Sandler Neutral → Overweight
Oct-26-22 Upgrade Goldman Neutral → Buy
Oct-13-22 Upgrade Stifel Hold → Buy
Oct-07-22 Upgrade Argus Hold → Buy
Sep-28-22 Upgrade BMO Capital Markets Market Perform → Outperform
Sep-28-22 Upgrade Mizuho Neutral → Buy
Sep-28-22 Upgrade Robert W. Baird Neutral → Outperform
Apr-18-22 Upgrade Wells Fargo Equal Weight → Overweight
Mar-08-22 Downgrade Stifel Buy → Hold
Mar-03-22 Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-04-22 Downgrade BMO Capital Markets Outperform → Market Perform
Feb-04-22 Reiterated Barclays Equal Weight
Feb-04-22 Reiterated BofA Securities Neutral
Feb-04-22 Reiterated Cowen Outperform
Feb-04-22 Reiterated Morgan Stanley Overweight
Feb-04-22 Reiterated Needham Buy
Feb-04-22 Reiterated Oppenheimer Outperform
Feb-04-22 Reiterated RBC Capital Mkts Sector Perform
Feb-04-22 Reiterated Robert W. Baird Neutral
Feb-04-22 Reiterated Wedbush Neutral
Feb-04-22 Reiterated Wells Fargo Equal Weight
Feb-04-22 Reiterated Wolfe Research Peer Perform
Jan-13-22 Downgrade Guggenheim Buy → Neutral
Jan-12-22 Downgrade Piper Sandler Overweight → Neutral
Dec-10-21 Resumed Raymond James Mkt Perform
Dec-09-21 Resumed Wells Fargo Equal Weight
Dec-06-21 Initiated Goldman Neutral
Nov-19-21 Initiated BMO Capital Markets Outperform
Sep-23-21 Initiated Needham Buy
Jun-18-21 Upgrade Piper Sandler Neutral → Overweight
Jun-14-21 Reiterated Truist Buy
Jun-11-21 Upgrade Bernstein Mkt Perform → Outperform
Jun-10-21 Upgrade UBS Neutral → Buy
Jun-08-21 Upgrade Atlantic Equities Underweight → Neutral
Jun-08-21 Reiterated Barclays Equal Weight
Jun-08-21 Upgrade Citigroup Sell → Neutral
Jun-08-21 Reiterated H.C. Wainwright Buy
Jun-08-21 Reiterated Jefferies Buy
Jun-08-21 Reiterated Morgan Stanley Overweight
Jun-08-21 Reiterated RBC Capital Mkts Sector Perform
Jun-08-21 Upgrade Robert W. Baird Underperform → Neutral
Jun-08-21 Reiterated Stifel Buy
Jun-08-21 Upgrade William Blair Mkt Perform → Outperform
Jun-07-21 Upgrade BofA Securities Underperform → Neutral
Jun-07-21 Upgrade Cowen Market Perform → Outperform
Jun-07-21 Upgrade Raymond James Underperform → Mkt Perform
Feb-05-21 Downgrade DZ Bank Buy → Hold
Jan-29-21 Upgrade Stifel Hold → Buy
Nov-10-20 Upgrade DZ Bank Hold → Buy
Nov-09-20 Downgrade Atlantic Equities Neutral → Underweight
Nov-09-20 Downgrade BofA Securities Neutral → Underperform
Nov-09-20 Downgrade Cowen Outperform → Market Perform
Nov-09-20 Reiterated H.C. Wainwright Buy
Nov-04-20 Upgrade BofA Securities Underperform → Neutral
Nov-04-20 Upgrade Jefferies Hold → Buy
Nov-04-20 Upgrade Wells Fargo Equal Weight → Overweight
Oct-28-20 Initiated UBS Neutral
Jul-27-20 Upgrade Morgan Stanley Underweight → Overweight
Jun-22-20 Downgrade Barclays Overweight → Equal Weight
Jun-22-20 Reiterated RBC Capital Mkts Sector Perform
Jun-09-20 Downgrade Bernstein Outperform → Mkt Perform
Apr-23-20 Downgrade Citigroup Neutral → Sell
Apr-23-20 Downgrade Raymond James Mkt Perform → Underperform
Mar-31-20 Initiated Wolfe Research Peer Perform
Feb-27-20 Initiated Barclays Overweight
Jan-27-20 Upgrade Canaccord Genuity Hold → Buy
Dec-13-19 Upgrade Credit Suisse Underperform → Neutral
Dec-02-19 Downgrade Robert W. Baird Neutral → Underperform
View All

Biogen Inc Stock (BIIB) Latest News

pulisher
05:11 AM

Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Connor Clark & Lunn Investment Management Ltd. - MarketBeat

05:11 AM
pulisher
03:11 AM

Biogen Inc. (NASDAQ:BIIB) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

03:11 AM
pulisher
Mar 13, 2025

Zurcher Kantonalbank Zurich Cantonalbank Raises Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Mar 13, 2025
pulisher
Mar 13, 2025

Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.

Mar 13, 2025
pulisher
Mar 13, 2025

Edgestream Partners L.P. Increases Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Mar 13, 2025
pulisher
Mar 13, 2025

Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Wealthfront Advisers LLC - MarketBeat

Mar 13, 2025
pulisher
Mar 13, 2025

Multiple Sclerosis Therapeutics Market Projected To Witness Substantial Growth, 2025-2032: Biogen Inc., - EIN News

Mar 13, 2025
pulisher
Mar 13, 2025

Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Daiwa Securities Group Inc. - MarketBeat

Mar 13, 2025
pulisher
Mar 12, 2025

20,831 Shares in Biogen Inc. (NASDAQ:BIIB) Bought by AlphaQuest LLC - MarketBeat

Mar 12, 2025
pulisher
Mar 12, 2025

Amundi Raises Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Mar 12, 2025
pulisher
Mar 12, 2025

Marathon Trading Investment Management LLC Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Mar 12, 2025
pulisher
Mar 12, 2025

M&T Bank Corp Lowers Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Mar 12, 2025
pulisher
Mar 12, 2025

BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant - Nasdaq

Mar 12, 2025
pulisher
Mar 12, 2025

X-Elio inks VPPAs with Cisco, Biogen, others for 172 MW of US solar - Renewables Now

Mar 12, 2025
pulisher
Mar 12, 2025

X-ELIO closes six US PPAs with Cisco, Biogen, IDEXX, and Waters Corporation - PR Newswire

Mar 12, 2025
pulisher
Mar 12, 2025

Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR - Yahoo Finance

Mar 12, 2025
pulisher
Mar 12, 2025

18,715 Shares in Biogen Inc. (NASDAQ:BIIB) Bought by Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD - MarketBeat

Mar 12, 2025
pulisher
Mar 12, 2025

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD Makes New $8.34 Million Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Mar 12, 2025
pulisher
Mar 12, 2025

AMF Tjanstepension AB Has $9.04 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Mar 12, 2025
pulisher
Mar 12, 2025

Victory Capital Management Inc. Trims Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Mar 12, 2025
pulisher
Mar 12, 2025

Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Charles Schwab Investment Management Inc. - MarketBeat

Mar 12, 2025
pulisher
Mar 11, 2025

Biogen Bets Up to $550 Million for Rights to Epilepsy Drug - MSN

Mar 11, 2025
pulisher
Mar 11, 2025

Biogen Stock Is Mutating Into a Value Play - MSN

Mar 11, 2025
pulisher
Mar 11, 2025

Stephen A. Sherwin Sells 8,760 Shares of Biogen Inc. (NASDAQ:BIIB) Stock - MarketBeat

Mar 11, 2025
pulisher
Mar 11, 2025

Biogen to Participate in the Stifel 2025 Virtual CNS Forum - Biogen | Investor Relations

Mar 11, 2025
pulisher
Mar 11, 2025

Sage Therapeutics stock rated Underperform at BofA (SAGE) - Seeking Alpha

Mar 11, 2025
pulisher
Mar 11, 2025

Sage moved to Underperform at BofA; says Biogen’s buyout impact has passed - MSN

Mar 11, 2025
pulisher
Mar 11, 2025

Biogen Initiates Dosing of Phase 3 Study of Felzartamab -March 11, 2025 at 09:47 am EDT - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Biogen patents new GPR17 antagonists for multiple sclerosis - BioWorld Online

Mar 11, 2025
pulisher
Mar 11, 2025

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients - Biogen | Investor Relations

Mar 11, 2025
pulisher
Mar 11, 2025

Biogen's Breakthrough Drug Enters Final Testing Phase for Critical Kidney Transplant Complication - StockTitan

Mar 11, 2025
pulisher
Mar 11, 2025

Biogen Target of Unusually Large Options Trading (NASDAQ:BIIB) - Defense World

Mar 11, 2025
pulisher
Mar 11, 2025

Biogen Director Makes a Major Stock Move! - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Candriam S.C.A. Has $30.88 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Mar 11, 2025
pulisher
Mar 10, 2025

Biogen Inc. (NASDAQ:BIIB) Shares Bought by E Fund Management Co. Ltd. - MarketBeat

Mar 10, 2025
pulisher
Mar 10, 2025

Biogen director Stephen Sherwin sells shares for $1.31 million - Investing.com

Mar 10, 2025
pulisher
Mar 10, 2025

Decoding Biogen's Options Activity: What's the Big Picture? - Benzinga

Mar 10, 2025
pulisher
Mar 10, 2025

A Mother's Love and Daughter's Fight: Facing Alzheimer's Together - CBS News

Mar 10, 2025
pulisher
Mar 10, 2025

Investors Purchase Large Volume of Biogen Put Options (NASDAQ:BIIB) - MarketBeat

Mar 10, 2025
pulisher
Mar 10, 2025

What’s driving pharma’s layoffs in 2025 - PharmaVoice

Mar 10, 2025
pulisher
Mar 10, 2025

Oppenheimer & Co. Inc. Sells 1,826 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Mar 10, 2025
pulisher
Mar 10, 2025

Biogen (NASDAQ:BIIB) Shares Up 3.5%What's Next? - MarketBeat

Mar 10, 2025
pulisher
Mar 10, 2025

Leigh Syndrome Treatment Market Poised for Substantial Growth - openPR

Mar 10, 2025
pulisher
Mar 10, 2025

State of Michigan Retirement System Grows Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Mar 10, 2025
pulisher
Mar 10, 2025

SVB Wealth LLC Purchases New Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Mar 10, 2025
pulisher
Mar 10, 2025

Mutual of America Capital Management LLC Sells 3,314 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Mar 10, 2025
pulisher
Mar 09, 2025

SBI Securities Co. Ltd. Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Mar 09, 2025
pulisher
Mar 09, 2025

Generali Investments CEE investicni spolecnost a.s. Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Mar 09, 2025
pulisher
Mar 09, 2025

Banco Santander S.A. Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Mar 09, 2025
pulisher
Mar 08, 2025

Sanctuary Advisors LLC Sells 1,842 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Mar 08, 2025
pulisher
Mar 08, 2025

Biogen (NASDAQ:BIIB) Stock Price Up 3.5%Here's What Happened - MarketBeat

Mar 08, 2025

Biogen Inc Stock (BIIB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$113.35
price down icon 0.56%
drug_manufacturers_general SNY
$57.75
price up icon 0.10%
drug_manufacturers_general PFE
$25.60
price down icon 0.43%
$312.64
price up icon 0.04%
drug_manufacturers_general NVS
$109.11
price up icon 0.43%
drug_manufacturers_general MRK
$94.71
price up icon 1.46%
Cap:     |  Volume (24h):